Systematic chemical and molecular profiling of MLL-rearranged infant acute lymphoblastic leukemia reveals efficacy of romidepsin
MetadataShow full item record
To address the poor prognosis of mixed lineage leukemia (MLL)-rearranged infant acute lymphoblastic leukemia (iALL), we generated a panel of cell lines from primary patient samples and investigated cytotoxic responses to contemporary and novel Food and Drug Administration-approved chemotherapeutics. To characterize representation of primary disease within cell lines, molecular features were compared using RNA-sequencing and cytogenetics. High-throughput screening revealed variable efficacy of currently used drugs, however identified consistent efficacy of three novel drug classes: proteasome inhibitors, histone deacetylase inhibitors and cyclin-dependent kinase inhibitors. Gene expression of drug targets was highly reproducible comparing iALL cell lines to matched primary specimens. Histone deacetylase inhibitors, including romidepsin (ROM), enhanced the activity of a key component of iALL therapy, cytarabine (ARAC) in vitro and combined administration of ROM and ARAC to xenografted mice further reduced leukemia burden. Molecular studies showed that ROM reduces expression of cytidine deaminase, an enzyme involved in ARAC deactivation, and enhances the DNA damage-response to ARAC. In conclusion, we present a valuable resource for drug discovery, including the first systematic analysis of transcriptome reproducibility in vitro, and have identified ROM as a promising therapeutic for MLL-rearranged iALL.
Showing items related by title, author, creator and subject.
Constitutive Activation of RAS/MAPK Pathway Cooperates with Trisomy 21 and Is Therapeutically Exploitable in Down Syndrome B-cell LeukemiaLaurent, A.P.; Siret, A.; Ignacimouttou, C.; Panchal, K.; Diop, M.; Jenni, S.; Tsai, Y.C.; Roos-Weil, D.; Aid, Z.; Prade, N.; Lagarde, S.; Plassard, D.; Pierron, G.; Daudigeos, E.; Lecluse, Y.; Droin, N.; Bornhauser, B.C.; Cheung, Laurence ; Crispino, J.D.; Gaudry, M.; Bernard, O.A.; Macintyre, E.; Barin Bonnigal, C.; Kotecha, Rishi ; Geoerger, B.; Ballerini, P.; Bourquin, J.P.; Delabesse, E.; Mercher, T.; Malinge, S. (2020)©2020 American Association for Cancer Research. PURPOSE: Children with Down syndrome (constitutive trisomy 21) that develop acute lymphoblastic leukemia (DS-ALL) have a 3-fold increased likelihood of treatment-related ...
Cheung, Laurence ; de Kraa, Rebecca; Oommen, Joyce; Chua, Grace-Alyssa; Singh, Sajla; Hughes, Anastasia M; Ferrari, Emanuela; Ford, Jette; Chiu, Sung K; Stam, Ronald W; Kees, Ursula R; Malinge, Sébastien; Kotecha, Rishi (2021)Background: Infants with KMT2A-rearranged B-cell precursor acute lymphoblastic leukemia (ALL) have poor outcomes. There is an urgent need to identify novel agents to improve survival. Proteasome inhibition has emerged as ...
Siveen, K.; Sikka, S.; Surana, R.; Dai, X.; Zhang, J.; Kumar, Alan Prem; Tan, B.; Sethi, G.; Bishayee, A. (2013)Signal transducers and activators of transcription (STATs) comprise a family of cytoplasmic transcription factors that mediate intracellular signaling that is usually generated at cell surface receptors and thereby transmit ...